GlassScriptPhysician profile
Peggi Ryan
NPI 1366419582
$5,703.47
in general payments reported to CMS, 2019-2025
46 companies · $1,221 in 2025
The $1,221 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,019 · 2022: $1,222 · 2023: $902 · 2024: $1,339 · 2025: $1,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,413 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,413.47 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,419.91 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $537.77 | 2021-2025 | |
| Novo Nordisk INC | $433.03 | 2021-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $301.28 | 2021-2024 | |
| Lilly USA, LLC | $284.99 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $275.01 | 2021-2025 | Otezla, Repatha, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $267.55 | 2022-2025 | Caplyta |
| Pfizer INC. | $192.32 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $183.35 | 2022 | |
| Philips North America LLC | $141.17 | 2023-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Aimmune Therapeutics, INC. | $116.41 | 2024-2025 | Zenpep |
| Novartis Pharmaceuticals Corporation | $114.37 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $105.20 | 2021-2025 | Rexulti |
| Nevro Corp. | $99.24 | 2023-2024 | Senza |
| Nestle Healthcare Nutrition INC. | $96.82 | 2021-2023 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $95.56 | 2021-2024 | Yupelri |
| Scilex Pharmaceuticals INC. | $82.69 | 2022-2025 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.36 | 2021 | |
| Alkermes, INC. | $79.77 | 2024-2025 | Aristada, Lybalvi, Vivitrol |
| Sunovion Pharmaceuticals INC. | $62.04 | 2021-2022 | |
| Indivior INC. | $60.55 | 2021-2024 | Sublocade |
| Glaxosmithkline, LLC. | $58.57 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $54.27 | 2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.60 | 2024 | Synjardy, Jardiance, Tradjenta |
| Axsome Therapeutics, INC. | $44.16 | 2024-2025 | Auvelity |
| Dexcom, INC. | $40.56 | 2023-2024 | Dexcom G6 Transmitter |
| Tonix Medicines, INC. | $31.74 | 2025 | Tonmya |
| Takeda Pharmaceuticals U.S.A., INC. | $29.03 | 2021 | |
| Globus Medical, INC. | $26.33 | 2025 | Senza |
| Hologic Sales and Service, LLC | $26.24 | 2025 | Thinprep 2000 Processor, Aptima |
| Bardy Diagnostics, INC. | $25.48 | 2021 | |
| Eisai INC. | $24.57 | 2021 | |
| Cequr Corporation | $24.35 | 2024 | Cequr Simplicity |
| Electromed, INC. | $23.34 | 2022 | |
| Advanced Respiratory, INC | $23.23 | 2021 | |
| Boston Scientific Corporation | $21.89 | 2022 | |
| Lifescan, INC. | $21.25 | 2023 | |
| Xeris Pharmaceuticals, INC. | $19.17 | 2023 | Gvoke Hypopen |
| Grifols USA, LLC | $18.46 | 2024 | Prolastin-C Liquid |
| Biohaven Pharmaceuticals, INC. | $18.33 | 2021 | |
| Paratek Pharmaceuticals, INC. | $17.93 | 2023 | Nuzyra |
| Baxter Healthcare | $17.67 | 2023 | Hillrom - Life 2000 Ventilation System |
| Sumitomo Pharma America, INC. | $16.95 | 2024 | Gemtesa |
| Inogen, INC. | $16.15 | 2022 | |
| Exact Sciences Corporation | $14.55 | 2025 | Cologuard Collection Kit |
| Uswm, LLC | $13.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peggi Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.